Acrivastine and cariprazine increase sedation. Be careful / watch out.
almotriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
amifostine, cariprazine. Both potentiate the effects of the other by blocking the antihypertensive channel. Be careful / watch out. Because of their alpha-adrenergic antagonism, atypical antipsychotics have the potential to potentiate the effects of certain antihypertensive drugs. Monitor blood pressure and adjust dose accordingly.
Amisulpride and cariprazine increase sedation. Be careful / watch out.
Asenapine and cariprazine increase sedation. Be careful / watch out.
Transdermal asenapine and cariprazine increase sedation. Be careful / watch out.
Atazanavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Belzutifan decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. If co-administration of belzutifan with sensitive CYP3A4 substrates cannot be avoided, consider increasing the dose of the sensitive CYP3A4 substrate according to the prescribing information.
Cariprazine increases the toxicity of benazepril through pharmacodynamic synergism. Be careful / watch out. Increases the risk of hypotension.Benazepril increases the toxicity of cariprazine through pharmacodynamic synergism. Be careful / watch out. Increases the risk of hypotension.
brexanolone, cariprazine. Both increase the toxicity of the other through sedation. Be careful / watch out.
Cariprazine increases the toxicity of long-acting buprenorphine for injection through pharmacodynamic synergism. Adjust/monitor therapy closely. Concomitant use of buprenorphine and benzodiazepines or other CNS depressants increases the risk of adverse events, including overdose, respiratory depression, and death. Discontinuation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher treatment level may be appropriate to reduce CNS depressant effects. In other cases, it may be appropriate to reduce the prescription of a benzodiazepine or other CNS depressant, or reduce it to the lowest effective dose.
cariprazine, captopril. Both potentiate the toxicity of the other through pharmacodynamic synergism. Be careful / watch out. Both drugs lower blood pressure. Monitor blood pressure.
cenobamate, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out.
Clarithromycin increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Cobicistat increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Conivaptan increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Cariprazine and daridorexant increase sedation. Adjust/monitor therapy closely. Concomitant use increases the risk of CNS depression, which can lead to further impairment of psychomotor performance and impairment of time of day.
Darunavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Cariprazine and deuterabenazine potentiate antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Adjust/monitor therapy closely. The risk of parkinsonism, neuroleptic malignant syndrome and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.Cariprazine and deutetrabenazine increase sedation. Be careful / watch out.
dextromethorphan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Difelikefalin and cariprazine increase sedation. Be careful / watch out.
dihydroergotamine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Duvelisib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. increases the level or effect of
elagolix decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Elagolix is a weak to moderate CYP3A4 inducer. Monitor CYP3A substrates when used concomitantly. If necessary, consider increasing the CYP3A substrate dose.
eletriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Elvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
encorafenib, cariprazine. affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out. Encorafenib inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Co-administration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
Ergoloid mesylate, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
ergotamine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
intranasal esketamine, cariprazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely.
Fedratinib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Adjust the dose of drugs that are CYP3A4 substrates as needed.
Cariprazine decreases the effect of fenfluramine through pharmacodynamic antagonism. Be careful / watch out. Strong serotonin receptor antagonists can reduce the effectiveness of fenfluramine. Monitor accordingly if used concomitantly.
fentanyl, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
flibanserin, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Fosamprenavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
frovatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Cariprazine and ganaxolone increase sedation. Be careful / watch out.
Grapefruit increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Idelalisib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Imatinib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Indinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Cariprazine reduces the effect of insulin degludec by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.
Cariprazine reduces the effect of insulin degludec/insulin aspart by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.
Cariprazine decreases the effects of insulin inhaled by others (see comment). Be careful / watch out. Comment: Atypical antipsychotics have been associated with hyperglycemia, which can impair glycemic control; antidiabetic drug doses may need to be adjusted and more frequent glucose monitoring may be required.
Isoniazid increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Istradefylline increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical studies. This effect was not observed with istradefylline 20 mg/day. Consider reducing the dose of sensitive CYP3A4 substrates.
Itraconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Ketoconazole increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
lasmiditan, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out. The concomitant use of Lasmiditan and other CNS depressants, including alcohol, has not been studied in clinical studies. Lasmiditan can cause sedation as well as other cognitive and/or neuropsychiatric side effects.
lemborexant, cariprazine. Both potentiate the effect of the other through sedation. Adjust/monitor therapy closely. Dose adjustment may be required when lemborexant is co-administered with other CNS depressant medicinal products due to potential additive effects.
Lenacapavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates started within 9 months of the last subcutaneous lenacapavir dosing, which may increase the potential risk of CYP3A4 substrate adverse reactions.
Levoketoconazole increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Levomilnacipran, Cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Linezolid, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
lithium, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Lopinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
lorcaserin, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
meperidine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Cariprazine decreases the effect of metformin through pharmacodynamic antagonism. Be careful / watch out.
methadone, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
methylergonovine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Cariprazine increases the toxicity of methylphenidate through pharmacodynamic antagonism. Be careful / watch out. When these drugs are used in combination, close monitoring should be done for evidence of an altered clinical response to methylphenidate or an antipsychotic.
intranasal midazolam, cariprazine. Both potentiate the effects of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and contribute to a potent and/or sustained drug effect.
Milnacipran, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Naratriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Nefazodone increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Nelfinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Nicardipine increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
oliceridine, cariprazine. Both potentiate the toxicity of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. With concomitant use, severe sedation, respiratory depression, coma and death may occur. Reserve the concomitant prescription of these drugs for patients for whom other treatment options are unsuitable. Limit doses and duration to the minimum necessary. Pay close attention to signs of respiratory depression and sedation.
paroxetine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
phenelzine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Posaconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
procarbazine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
promethazine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Quinidine increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
remimazolam, cariprazine. Both increase the toxicity of the other through sedation. Adjust/monitor therapy closely. Concomitant use may result in severe sedation, respiratory depression, coma and/or death. Vital signs should be continuously monitored during sedation and the recovery period, if administered simultaneously. Carefully titrate the dose of remizolam when co-administered with opioid analgesics and/or sedatives/hypnotics.
Ribociclib increases the level or effect of cariprazine by affecting the metabolism of the hepatic/intestinal enzyme CYP3A4. Be careful / watch out.
Ritonavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Rucaparib increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Adjust the dose of CYP3A4 substrates when clinically indicated.
Saquinavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
selegiline, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Sodium sulfate/magnesium sulfate/potassium chloride potentiate the effects of cariprazine by an unknown mechanism. Be careful / watch out. Watch closely for signs of increased CNS depression when a higher dose of magnesium sulfate is used in conjunction with a CNS depressant.
Sodium sulfate/potassium sulfate/magnesium sulfate potentiate the effects of cariprazine by an unknown mechanism. Be careful / watch out. Watch closely for signs of increased CNS depression when a higher dose of magnesium sulfate is used in conjunction with a CNS depressant.
stiripentol, cariprazine. affect the metabolism of the hepatic/intestinal enzyme CYP3A4. Adjust/monitor therapy closely. Stiripentol is an inhibitor and inducer of CYP3A4. Monitor CYP3A4 substrates co-administered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dose adjustment.stiripentol, cariprazine. Both potentiate the effect of the other through sedation. Be careful / watch out. Concomitant use of medicinal products with CNS depressant effects with thalidomide should be avoided due to the risk of additional sedative effects.
sumatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
intranasal sumatriptan, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Tazemetostat decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out.
Tecovirimat decreases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Be careful / watch out. Tecovirimate is a weak inducer of CYP3A4. Monitor the potency of sensitive CYP3A4 substrates when co-administered.
Tipranavir increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
tranylcypromine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
venlafaxine, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Vilazodone, cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).
Voriconazole increases the level or effect of cariprazine by affecting the metabolism of the intestinal/hepatic enzyme CYP3A4. Adjust/monitor therapy closely. Concomitant use with strong CYP3A4 inhibitors requires a dose reduction of cariprazine. See the dose modification section of the drug monograph.
Zolmitriptan, Cariprazine. Mechanism of interaction not given. Be careful / watch out. Serotonin modulators may increase dopamine blockade and possibly increase the risk of neuroleptic malignant syndrome. Antipsychotic drugs can increase the serotonergic effects of serotonin modulators, which can lead to serotonin syndrome. Watch for signs of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).